SAN DIEGO--DuPont Pharmaceuticals, a component of DuPont's Life Science Enterprise, and privately held Structural Bioinformatics last week announced a strategic alliance for the discovery and development of small-molecule leads in a family of signaling proteins and other targets. The alliance is a multiyear agreement involving certain guaranteed and milestone payments with an overall value in excess of $100 million, assuming several successful products.
Under the terms of the agreement, DuPont will pay for technology access and for research support at Structural Bioinformatics. The two companies will collaborate to identify and optimize lead molecules targeted at receptors for several signaling proteins.
"SBI's approach is a cutting-edge attempt to address the challenging problem of interrupting protein-protein interactions," said Paul Friedman, president of DuPont Pharmaceuticals Research Laboratories.